Normal view MARC view ISBD view

Effect of gefitinib on clinically selected non small cell lung cancer and egfr mutation experience from a single center from india

In Journal of Thoracic Oncology
By: Prabhash K.
Contributor(s): Munshi A | Agarwal JP | Karimundackal G | Pramesh CS | Jambekar N | Desai S | Abhishek T | Mulerkar R | Purandare N | Noronha V | .
Material type: materialTypeLabelArticleSeries: Vol 6 Issues.Publisher: 2011Description: 1281.Subject(s): NSCLC, non-smoker, gefitinib | DDC classification: In: Journal of Thoracic OncologySummary: Background: Geftinib is an important drug in the anagement of NSCLC. It has been found to be effective in patients who are clinically selected. It has better activity in patients with EGFR mutations. It is commonly used in patients in first and second line setting. We retrospectively analyzed our prospectively collected data to assess the efficacy and safety of gefitinib in these patients. Mutation analysis was done on the paraffin blocks available by direct sequencing. Methods: The record of patients receiving Gefitinib was retrieved from the data entry done prospectively. Source document of these patients were the hospital file. These patients received Gefitinib treatment for the NSCLC. Patients were followed up every 2 months with scan, clinically and QOL to assess the efficacy. Patients were also evaluated for side effects. Skin side effects and loose motions were specially documented. Scan was evaluated by radiologist who was designated for the same. Results: There were 54 patients who received Gef
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR15014

Background: Geftinib is an important drug in the anagement of NSCLC. It has been found to be effective in patients who are clinically selected. It has better activity in patients with EGFR mutations. It is commonly used in patients in first and second line setting. We retrospectively analyzed our prospectively collected data to assess the efficacy and safety of gefitinib in these patients. Mutation analysis was done on the paraffin blocks available by direct sequencing.
Methods: The record of patients receiving Gefitinib
was retrieved from the data entry done prospectively. Source document of these patients were the hospital file. These patients received Gefitinib treatment for the NSCLC. Patients were followed up every 2 months with scan, clinically and QOL to assess the efficacy. Patients were also evaluated for side effects. Skin side effects and loose motions were specially documented. Scan was evaluated by radiologist who
was designated for the same.
Results: There were 54 patients who received Gef

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha